Showing 3731-3740 of 6412 results for "".
- FDA Gives Nod to First Particulate Placental Extracellular Matrix Medical Device for Wound Managementhttps://practicaldermatology.com/news/fda-gives-nod-to-first-particulate-placental-extracellular-matrix-medical-device-for-wound-management/2461574/The U.S. Food and Drug Administration cleared Convatec’s InnovaMatrix PD particulate placental extracellular matrix medical device for wound management. The InnovaMatrix PD medical device joins Convatec’s existing InnovaMatrix AC product as the first and only next-gener
- Dove Partners with LinkedIn in Effort to Help End Race-Based Hair Discrimination in the Workplacehttps://practicaldermatology.com/news/dove-partners-with-linkedin-in-effort-to-help-end-race-based-hair-discrimination-in-the-workplace/2461566/In an effort to help pass “The CROWN Act,” which aims to end race-based hair discrimination, Dove announced it is partnering with LinkedIn. The NEW CROWN 2023 Workplace Research Study, co-commissioned by Dove and LinkedIn, found that black women's hair is 2.5x more
- Relief Therapeutics Enrolls First Patients in Proof-of-Concept Trial of Epidermolysis Bullosa Treatmenthttps://practicaldermatology.com/news/relief-therapeutics-enrolls-first-patients-in-proof-of-concept-trial-of-epidermolysis-bullosa-treatment/2461563/Relief Therapeutics announced the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB). The primary aim of the study will be to assess changes in the skin microbiome (Staphylococcu
- Potential Notalgia Paresthetica Breakthrough: Oral Difelikefalin May Curb Persistent Itchhttps://practicaldermatology.com/news/potential-notalgia-paresthetica-breakthrough-oral-difelikefalin-may-curb-persistent-itch/2461553/Notalgia paresthetica—a nerve disorder characterized by a persistent itch in the upper back—is a common and underdiagnosed condition worldwide. To date, there are no U.S. Food and Drug Administration (FDA)-approved treatments specifically targeting this disorder. But a new s
- Merz Aesthetics, NWSL’s North Carolina Courage Expand Partnershiphttps://practicaldermatology.com/news/merz-aesthetics-partners-with-wsls-north-carolina-courage-to-fuel-confidence-on-and-off-field/2461532/Merz Aesthetics is expanding its sponsorship of the North Carolina Courage, two-time champions of the National Women’s Soccer League (NWSL). “This partnership is so meaningful for us at Merz Aesthetics,” says Patrick Urban, North America President, in
- Update: Two More Payers to Cover DermTech’s Melanoma Testhttps://practicaldermatology.com/news/update-two-more-payers-to-cover-dermtechs-melanoma-test/2461514/Two new payers plan to cover the DermTech Melanoma Test, making the foundational assay available to approximately 1.2 million more people. The new insurers are Blues plan in Hawaii and a physician-founded, member-focused and community-based not-for-profit health plan in New York. T
- First Patient Dosed in Phase II Clinical Trial of TLL018-205 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-ii-clinical-trial-of-tll018-205-for-pso/2461511/The first patient has been enrolled and dosed in a Phase II study evaluating the efficacy and safety of TLL-018 fpr moderate to severe plaque psoriasis. This study is sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd (Highlightll Pharmaceutical, USA). T
- Journey Medical Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosaceahttps://practicaldermatology.com/news/journey-medical-completes-enrollment-in-phase-3-clinical-trials-evaluating-dfd-29-for-the-treatment-of-papulopustular-rosacea/2461506/Journey Medical Corp. announced that it has fully enrolled and randomized all of the patients in its Phase 3 clinical program to assess the safety, efficacy and tolerability of DFD-29 (minocycline modified release capsules 40 mg) for the treatment of papulopustular rosacea, the company announced
- Enrollment Complete for Journey’s Phase 3 Trials of DFD-29 in Papulopustular Rosaceahttps://practicaldermatology.com/news/enrollment-complete-for-journeys-in-phase-3-trials-of-dfd-29-in-papulopustular-rosacea/2461492/Journey Medical Corporation’s Phase 3 clinical trial program of DFD-29 for papulopustular rosacea is now fully enrolled. The Phase 3 clinical trials are part of a collaboration with Dr. Reddy’s Laboratories Ltd. for the ongoing development and commercialization of the D
- Topline Results: Union's Oral Orismilast Improves PASI by Week 16 in Patients with Moderate to Severe PsOhttps://practicaldermatology.com/news/topline-results-unions-oral-orismilast-improves-pasi-by-week-16-in-patients-with-moderate-to-severe-pso/2461489/Oral orismilast performed well in adult patients with moderate to severe psoriasis, according to topline results from the IASOS Phase 2b study. Data from the 202 patients randomized and dosed in the study showed that all active arms of oral orismilast achieved the primary endp